Erythropoiesis‐stimulating agents and incident malignancy in chronic kidney and end‐stage renal disease: A population‐based study
Abstract Research investigating incident malignancy risk in erythropoiesis‐stimulating agent (ESA) users with chronic kidney disease (CKD) is lacking. We aimed to compare the incident cancer risk between ESA and non‐ESA users with CKD or end‐stage renal disease (ESRD). In this retrospective cohort s...
Saved in:
Main Authors: | Yu‐Shan Huang (Author), Ming‐Feng Li (Author), Mei‐Chen Lin (Author), Shih‐Hsiang Ou (Author), Jen‐Hung Wang (Author), Chien‐Wei Huang (Author), Kang‐Ju Chou (Author), Hua‐Chang Fang (Author), Po‐Tsang Lee (Author), Chih‐Yang Hsu (Author), Jin‐Shuen Chen (Author), Hsin‐Yu Chen (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2022-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Appropriate Use of Inpatient Erythropoiesis Stimulating Agents
by: Chenghao Cui, et al.
Published: (2024) -
Treatment of renal anemia: Erythropoiesis stimulating agents and beyond
by: Patrick Biggar, et al.
Published: (2017) -
Use of erythropoiesis-stimulating agents in obese hemodialysis patients
by: Sun-Hee Park
Published: (2018) -
Increases In Erythropoiesis Stimulating Agent (Esa) Use After Hospitalization Of End Stage Renal Disease (Esrd) Patients
by: T. Christopher Bond, et al.
Published: (2012) -
Anaemia and heart failure: is there still a role for erythropoiesis-stimulating agents?
by: Massimo Volpe, et al.
Published: (2017)